Wikimedia CommonsFoto: Poco a Poco. Cayman Islands Signs FATCA Agreement Increasing Pressure on Other Fund Domiciles
USA has reached a preliminary agreement with the Cayman Islands for the Caribbean nation to meet FATCA rules. This could act as pressure for other “tax havens” which for the moment have failed to adopt those rules.
The Cayman Islands have said they will comply with FATCA regulations which will come into force in July 2014, and for which the foundations for an intergovernmental agreement (IGA) have been laid, and, as recorded by Reuters, the official signature will be held soon
FATCA requires for foreign financial institutions to notify the U.S. tax authority (IRS) of the accounts held by U.S. citizens with more than $ 50,000. Financial institutions which do not comply will see their benefits in the U.S. undergo tax withholding of 30%, which in fact, in most cases, means evicting them from the country.
The Cayman Islands are a popular destination for registration of investment funds. The country has no income tax and is often referred to as a “tax haven”. According to industry sources, the thousands of hedge funds, private equity funds and mutual funds domiciled in Cayman Islands were in favor of reaching an agreement to preserve their access to the U.S. market.
The official signing of the FATCA agreement by Cayman Islands will put pressure on other low-tax countries which harbor investment instruments, such as Luxembourg, Bermuda and the British Virgin Islands. Ireland and Switzerland have already signed agreements with the U.S. for FATCA regulation in January and February this year.
August 19th will see the opening of a webpage for banks to register with the IRS and to ensure their compliance with FATCA. The deadline for registration is until April 25, 2014.
Wikimedia CommonsRBC Office, Zonamerica. Royal Bank of Canada Announced the Closure of its Uruguayan Branch
According to a statement distributed by email, the Royal Bank of Canada Wealth Management will close its Uruguay branch on the 31st of October and the 41 employees at the branch will be relocated to other offices of the Canadian bank. The bank has reported that its closure in Uruguay “is part of a strategic review” of its business in Latin America.
RBC has commenced to notify its customers of this decision, offering to transfer their funds to other branches of the bank either in Europe or North America.
Two months ago, RBC facilities in Uruguay suffered a raid at the request of Argentine Judge Norberto Oyarbide amid an investigation for alleged tax offenses. It so happens that the Argentine judge is in charge of a megacause in which he is investigating the transfer of dozens of footballers in money laundering maneuvers worth millions of dollars. However, RBC sources told the El Observador newspaper in Montevideo that the closedown of its business in this country is not related to this incident.
“The criminal investigation involving the Uruguay branch is a separate issue and RBC will continue to work with the authorities to resolve it,” a bank source informed the newspaper.
This raid has caused great concern amongst the international customers of the bank in Uruguay, 70% of who are Argentineans with, on average, about $600,000 in accounts in Uruguay.
The executive director of the Uruguyan Association of Private Banks and former BCU president, Julio deBrun, told the newspaperEl País that the RBC raid caused “concern” and warned that the episode is “a bad sign” because it affects “the image of the bank and of the country.”
Wikimedia CommonsFoto: Danielparker. Calamos Adds Two Portfolio Managers to High Yield Expertise
Calamos Investments announced the addition of two co-portfolio managers to its investment team. Jeremy Hughes, CFA, and Chris Langs, CFA, have joined Calamos with more than 40 years of collective investment experience. Most recently, Messrs. Hughes and Langs worked together at Aviva Investors overseeing high yield assets.
At Calamos, the pair will contribute their expertise to managing the firm’s fixed income/high yield strategies, including the Calamos High Income Fund. Like all Calamos strategies, the firm’s fixed income/high yield portfolios are managed within a team-driven structure.
“A team approach benefits our clients by ensuring continuity of process and philosophy. Each team has specialized responsibilities—in this case, fixed income/high yield—but all teams draw upon each other’s insights and research. This balance of specialization and collaboration gives us an edge in identifying opportunities in the fixed income/high yield market”, stated John P. Calamos, Sr., CEO and Global Co-Chief Investment Officer.
The addition of Messrs. Hughes and Langs to enhance management of the firm’s fixed income/high yield strategies continues a measured and strategic expansion of the Calamos investment team, including the addition of a Value Equity Team and a Long/Short Team in 2012, as well as numerous additional hires at all levels of the investment organization.
Wikimedia CommonsFoto: Daniel Schwen. AllianceBernstein adquiere W.P. Stewart, gestora especializada en growth
AllianceBernstein and W.P. Stewart have entered into a definitive agreement whereby AllianceBernstein will acquire W.P. Stewart, an equity investment manager that currently manages $2 billion in U.S., Global and EAFE concentrated growth equity strategies for institutional and retail clients, primarily in the U.S. and Europe. Upon completion of the acquisition, W.P. Stewart’s investment services will be added to AllianceBernstein’s equity offering. W.P. Stewart’s team of investment managers will remain in place and continue to manage their investment services as they do today. At the same time, they will gain access to AllianceBernstein’s global reach and research team,
“I’m excited to be adding W.P. Stewart’s complementary concentrated growth equity services and strong bench of talent to our equity platform,” said Peter S. Kraus, Chairman and Chief Executive Officer of AllianceBernstein. “While our equity business is well-positioned to deliver in many areas, we also understand that our clients want more options, particularly in concentrated strategies that can help improve alpha generation potential within their portfolios”
To help ensure a smooth transition, founding partner William P. Stewart, an esteemed investor with nearly 60 years of industry experience, will stay on through the earlier of the end of this year or the close of the transaction, at which point he will retire from the firm.
At the closing of the transaction, AllianceBernstein will pay W.P. Stewart shareholders $12 per share in cash and will issue to W.P. Stewart shareholders transferable contingent value rights entitling the holders to an additional cash payment of $4 per share if the assets under management in the acquired W.P. Stewart investment services reach $5 billion on or before the third anniversary of the closing. W.P. Stewart currently has approximately 5 million shares outstanding. The closing is expected to occur in approximately four to six months and is subject to customary closing conditions, including W.P. Stewart shareholder approval and requirements relating to retention of assets under management and cash.
Wikimedia CommonsBy auriarte. International Equity and Value Funds Benefit From Bond Fund Sell-Off
Morningstar reported estimated U.S. mutual fund asset flows for July 2013. Investors added $15.9 billion to long-term mutual funds in July, driven by inflows of $7.9 billion into international-equity funds. Outflows from taxable-bond funds ebbed to $1.3 billion after record outflows of $43.7 billion in June, with investors continuing to favor bank-loan and nontraditional bond funds at the expense of more traditional intermediate-term bond categories.
Detroit’s bankruptcy filing kept municipal-bond funds in heavy redemptions; the category group lost $10.3 billion in July to mark the fifth straight month of outflows.
Value offerings led the way among equity funds, which was likely a result of yield-starved fixed-income investors seeking dividend income. Large-value funds collected $3.3 billion, the category’s strongest inflow since February 2007.
JPMorgan led all providers with inflows of $3.4 billion. Dimensional Fund Advisors, Oakmark, Principal Funds, and MFS have also gained market share over the last year.
Investors pulled $7.5 billion from PIMCO Total Return in July, its third month of outflows. The fund has seen outflows of $18.4 billion over the previous three months compared with inflows of $21.5 billion over the 16-month period from January 2012 through April 2013.
Despite declining fund use among advisors, traditional mutual fund managers, particularly large fund complexes, are positioned to play a leading role in the next phase of the ETF revolution, the rollout of active ETFs. This and other findings are included in a report recently released by Cogent Research, a Market Strategies International company. The report, Advisor Brandscape, is conducted annually and is based on a survey among a nationally representative sample of over 1,700 financial advisors in the U.S.
In the last six years, the proportion of advisors selling ETFs has increased dramatically, from less than half (46%) of advisors in 2007 to nearly three-quarters (73%) who use them today. In that same period, advisors’ allocations to ETFs have more than doubled, from 5% in 2007 to 12% in 2013. According to Cogent, most of the ETF gains thus far have come at the expense of mutual funds. Furthermore, for the first time ever, advisors now say they are as likely to invest new dollars in ETFs as they are to invest in mutual funds. However, as interest in active ETFs builds, it appears that traditional fund managers are well positioned to capture (or retain) a portion of future active ETF flows.
“While provider preferences certainly exist in the ETF category, many advisors remain relatively agnostic when it comes to choosing ETFs, particularly those tracking broad indexes,” says Meredith Rice, Senior Product Director and author of the Advisor Brandscape report. “However, the rules of engagement will change significantly when it comes to how advisors approach selecting actively managed ETFs. And that is where traditional active managers, even those late to the game, may find some real traction.”
While these findings may come as good news for active managers considering entry into the ETF marketplace, a potential downside is that advisors, while they are open to paying more for actively managed ETFs, expect these products to be less expensive than their actively managed mutual fund cousins.
“The potential pricing issues will certainly give some mutual fund companies pause,” says Rice. “But they need to look back over the past six years of ETF history, and ask themselves if they are willing to pass on the next wave of ETFs.”
Wikimedia CommonsFoto: bradley j. Invertir en farmacéuticas: una receta para ganar a largo plazo
The ebbs and flows of pharmaceutical stock prices relative to their underlying fundamentals over the last two decades have provided yet another example of the potential benefits of value investing. This is the main conclusion of a White Paper signed by Brandes Investment Partners, a Value Investment Specialist with nearly $25 bn under management, established in San Diego, California, in 1974.
Additionally, according to Brandes’ review, the changing performance cycles of pharmaceutical stocks underscore the patience and fortitude required to see through negative investor sentiment and industry headwinds.
The circumstances and conditions under which the pharma industry returned to favor, as shown in Exhibit 1, came amid the great recession, the storm of confusion over health care reform, and without the fanfare or arrival of any material new blockbuster drugs. This, to us, is yet another example of how the value-investing story often plays out.
Solid Businesses Bought at Attractive Prices
Like the current situation with pharmaceutical stocks’ return to investor favor,4 with a fundamental, value- based investment strategy, there is often no need for an extraordinary corporate event, exceptional execution or especially energizing macroeconomic forces for value to be recognized in the portfolio. In many cases, it is simply a solid business bought at an attractive price that is sufficient, if given the time to perform.
Brandes points out that this could be the most instructive lesson from the recent pharmaceutical cycle. It’s been said that there really are no value or growth stocks per se, just companies with fluctuating valuations at various stages of the business or market cycle. Over time they may pass in, and eventually out, of the value and growth categories. That a company’s fundamentals would gradually fluctuate over time is not especially surprising given the dynamics and vagaries of ever-changing markets and economies. The key from a value investor’s perspective is to recognize that good companies move in and out of fashion over time, purchase them when they are out of favor and under-priced, and have the discipline to sell when they reach estimates of fair value.
Pharmaceutical Industry Performance Cycles
Brandes takes a look back at pharma stocks’ performance cycles.
Almost 20 years ago, in a contentious and politically charged healthcare environment strikingly similar to today, pharmaceutical stocks sat poised on a launching pad in the eyes of investors, seemingly ready to either vault into the stratosphere or implode at ignition depending upon the fate of the pending health care reform legislation colloquially known at the time as Hillarycare. When the plan was defeated in 1994, share prices of the major pharmaceutical companies within the MSCI World Index soared starting that year and as the decade of the 1990s came to a close, as these companies were freed from the perception of potentially excessive governmental regulation and benefited from a roster of blockbuster drugs.
At the start of the new millennium, pharma share prices within the MSCI World Index hit all-time highs in the early 2000s as the growth prospects for an increasingly sophisticated and vitally important industry, just a few years away from catering to a soon retiring baby boomer generation, looked brighter than ever. Although Brandes Investment Patners were attracted to the fundamental business case for many of these companies, the high prices the market ascribed to them kept them from including these companies in the portfolios at the time.
Uncertainties Had Driven Prices Down by the Mid-2000s
As it’s inclined to do, however, uncertainty then visited the thriving pharma industry in the form of competitive and regulatory challenges, and as the first decade of the new century progressed, both the outlook and share prices for large pharmaceutical companies within the MSCI World Index changed course and fell considerably by the mid-2000s. During that time, significant market concerns including the following began to weigh on pharma share prices:
Looming expiration of valuable drug patents
Declining research & development (R&D) productivity due to longer and more expensive clinical trials and greater U.S. Food and Drug Administration scrutiny
Renewed and even more substantial healthcare reform pressures in the United States and globally
The market responded by re-rating pharmaceutical companies to much lower multiples than it was willing to apply beforehand. Suddenly, the Golden Age of Pharma was ending and the previously bright outlook for a rapidly growing industry was dimming, and their share prices responded accordingly starting in the mid-2000s, as mentioned above.
At the time the Brandes Global Equity Strategy began purchasing a number of the major pharmaceutical companies in 2004, the 12/31/2004 forward price-to-earnings ratio of the MSCI World-Pharmaceuticals had dropped to 16.2x. As is usually the case, P/Es had come down from lofty levels because the outlook for pharmas was not nearly as sanguine as it previously had been.
Fast Forward to 2013, Pharmaceutical Stock Prices Have Risen Again
Year to date through the end of the second quarter 2013, while pharma stocks within the MSCI World Index were on an upswing, their recent full cycle from high flyer, to laggard, and back again, is retracing a fairly familiar value pattern. A number of factors may have influenced renewed investor interest in pharma companies recently. These include the resiliency of the businesses amid changing investor perceptions, cash flow generation, conservative balance sheets as well as increases in dividends and share-buyback activity, as shown in Exhibit 2. Despite the recovery in share prices, Brandes Investment Partners still finds these companies attractively valued and they represent a meaningful allocation in the portfolio.
Wikimedia CommonsFoto: Markus Bernet. DeAWM ficha nuevo responsable de wealth management para Latinoamérica
Deutsche Asset & Wealth Management announced today that Felipe Godard will join the firm as a Managing Director and Head of Wealth Management, Latin America, effective October 1, 2013. He will be based in Geneva, Switzerland and will report to Haig Ariyan and Chip Packard, Co-Heads of Wealth Management, Americas and into the Executive Management Board of the Swiss banking entity, chaired by Marco Bizzozero, CEO Deutsche Bank Switzerland and Head of Wealth Management for EMEA.
Ariyan said: “Felipe is an experienced and talented professional who has a deep understanding of the evolving investment needs of ultra-high-net-worth families and individuals.”
Packard added: “Latin America is strategically important to our wealth management franchise. We are excited to have Felipe join the team to lead our efforts in delivering the Bank’s global capabilities to clients across the region.”
Godard will join the Firm from Credit Suisse in Switzerland, where he was Head of Advisory, Solutions and Investments for the Latin American Private Bank. Prior to joining Credit Suisse in 2010, Godard worked for J. P. Morgan in Geneva for 11 years where he headed the Latin American Team and later took responsibility for the Eastern European and Swiss markets for the Private Bank.
In June, Dutsche Asset and Wealth Management appointed Raphael Zagury as Head of Key Client Partners and Wealth Investment Advisory for Latin America from Bank of America Merrill Lynch. Additionally, Antonio Braun joined from J.P. Morgan as a Senior Relationship Manager, focusing on the Mexico market. Caroline Kitidis joined in August as Head of Key Client Partners & Wealth Investment Advisory for the Americas from Goldman Sachs.
. LarrainVial Appoints LatAm's Fixed Income "Dream Team"
On the first of September, Pedro Laborde and Felipe Rojas will become part LarrainVial’s team, one of the leading financial institutions in Latin America.
Rojas has agreed to join LarrainVial AGF to be in charge of the Latin American corporate debt funds, and will do so just a few days after leaving Cruz del Sur, where he earned the honor of becoming the only Latin American in Citywire’s global list of top 1000 mutual fund managers.
Pedro Laborde, who has extensive experience in the investment area and has worked with Rojas for a long time, will serve as manager for Credit Strategies.
Rojas’ duties will begin on the 1st of September, as he commented to Funds Society.
With a presence in Chile, Peru, Colombia and the United States, LarrainVial, which was founded in 1934, is one of the oldest and most important investment firms within the Chilean market. It currently manages assets worth 14,400 million dollars.
Wikimedia CommonsFoto: Sasha Kargaltsev. GAIN Capital contrata a Peter Cronin como director Ventas Institucionales para EMEA
GAIN Capital Holdings, a global provider of online trading services, has appointed Peter Cronin as Managing Director and Head of EMEA GTX Sales. Peter Cronin will be responsible for growing GTX, GAIN Capital’s institutional business, in Europe, the Middle East and Africa. He will report directly to Executive Vice President and Head of GTX, Joseph Wald, and has begun his new role in GTX’s London offices starting August 5th.
“Peter is an accomplished and talented banking professional who is moving to the FX ECN business at a time when the global foreign exchange industry is undergoing many exciting changes,” said GAIN Capital Executive Vice President and Head of GTX, Joseph Wald. At GTX, Peter Cronin will specifically be responsible for growing the institutional client base and ECN volumes, and building out the EMEA sales team.
Previously, Mr. Cronin was Head of EMEA e-Commerce at UBS Investment Bank, where he managed a 16-person sales team situated in Zurich, Lugano, Dubai and the United Kingdom. Mr. Cronin joined UBS in 2000, and during his 13 years tenure held senior roles focused on developing the bank’s e-Commerce business.
On July 16th, GTX reported average daily institutional volume of $18.4 billion for June 2013, an increase of 10% from May 2013 and 137% from June 2012.
